B
Brandy M. Ward
Researcher at Duke University
Publications - 2
Citations - 225
Brandy M. Ward is an academic researcher from Duke University. The author has contributed to research in topics: DNA vaccination & Adjuvant. The author has an hindex of 2, co-authored 2 publications receiving 200 citations.
Papers
More filters
Journal ArticleDOI
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
Mario Roederer,Brandon F. Keele,Stephen D. Schmidt,Rosemarie D. Mason,Hugh C. Welles,Hugh C. Welles,Will Fischer,Celia C. LaBranche,Kathryn E. Foulds,Mark K. Louder,Zhi-Yong Yang,Zhi-Yong Yang,John Paul Todd,Adam P. Buzby,Linh Mach,Ling Shen,Kelly E. Seaton,Brandy M. Ward,Robert T. Bailer,Raphael Gottardo,Wenjuan Gu,Guido Ferrari,S. Munir Alam,Thomas N. Denny,David C. Montefiori,Georgia D. Tomaras,Bette T. Korber,Martha Nason,Robert A. Seder,Richard A. Koup,Norman L. Letvin,Srinivas S. Rao,Gary J. Nabel,Gary J. Nabel,John R. Mascola +34 more
TL;DR: A nonhuman primate challenge model with simian immunodeficiency virus (SIV) shows that antibodies to the SIV envelope are necessary and sufficient to prevent infection, and identifies a two-amino-acid signature that alters antigenicity and confers neutralization resistance.
Journal ArticleDOI
Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques
M. Anthony Moody,Sampa Santra,Nathan Vandergrift,Laura L. Sutherland,Thaddeus C. Gurley,Mark S. Drinker,Ashley A. Allen,Shi-Mao Xia,R. Ryan Meyerhoff,Robert Parks,Krissey E. Lloyd,David Easterhoff,S. Munir Alam,Hua-Xin Liao,Brandy M. Ward,Guido Ferrari,David C. Montefiori,Georgia D. Tomaras,Robert A. Seder,Norman L. Letvin,Barton F. Haynes +20 more
TL;DR: An adjuvant based on an oil-in-water emulsion that incorporates Toll-like receptor (TLR) ligands to test whether triggering multiple pathogen-associated molecular pattern receptors could enhance immunogenicity found that the combination of TLR7/8 and TLR9 agonists was associated with the release of CXCL10, suggesting that the formulation may have optimally stimulated innate and adaptive immunity to elicit high titers of antibodies.